After years of stagnation in the treatment of neurodegenerative disorder amyotrophic lateral sclerosis (ALS), patients in the US could soon have two new treatment options – but their pricin
Amylyx Pharmaceuticals' efforts to bring its amyotrophic lateral sclerosis therapy AMX0035 to market in the US have run into some roadblocks, so an approval by Health Canada is a welcome re
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.